GEP20063860B - Chemically-modified human growth hormone conjugates - Google Patents

Chemically-modified human growth hormone conjugates

Info

Publication number
GEP20063860B
GEP20063860B GE5599A GEAP2002005599A GEP20063860B GE P20063860 B GEP20063860 B GE P20063860B GE 5599 A GE5599 A GE 5599A GE AP2002005599 A GEAP2002005599 A GE AP2002005599A GE P20063860 B GEP20063860 B GE P20063860B
Authority
GE
Georgia
Prior art keywords
growth hormone
human growth
chemically
modified human
conjugate
Prior art date
Application number
GE5599A
Other languages
English (en)
Inventor
Rory F Finn
Wei Lao
Ned R Siegel
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of GEP20063860B publication Critical patent/GEP20063860B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
GE5599A 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates GEP20063860B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20

Publications (1)

Publication Number Publication Date
GEP20063860B true GEP20063860B (en) 2006-06-26

Family

ID=23295870

Family Applications (1)

Application Number Title Priority Date Filing Date
GE5599A GEP20063860B (en) 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates

Country Status (25)

Country Link
EP (1) EP1453859A2 (zh)
JP (2) JP2005525302A (zh)
KR (2) KR20050044858A (zh)
CN (1) CN1608079A (zh)
AP (1) AP2004003050A0 (zh)
AU (1) AU2002356990A1 (zh)
BR (1) BR0214451A (zh)
CA (1) CA2467731A1 (zh)
CO (1) CO5580794A2 (zh)
EA (2) EA008505B1 (zh)
EC (1) ECSP045114A (zh)
GE (1) GEP20063860B (zh)
HR (1) HRP20040448A2 (zh)
HU (1) HUP0500997A2 (zh)
IL (1) IL162031A0 (zh)
IS (1) IS7268A (zh)
MA (1) MA27544A1 (zh)
MX (1) MXPA04004809A (zh)
NO (1) NO20042182L (zh)
OA (1) OA13063A (zh)
PL (1) PL374354A1 (zh)
RS (1) RS53104A (zh)
TN (1) TNSN04090A1 (zh)
WO (1) WO2003044056A2 (zh)
ZA (1) ZA200403907B (zh)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
AU2002357806A1 (en) * 2001-12-11 2003-06-23 Sun Bio, Inc. Novel monofunctional polyethylene glycol aldehydes
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
KR100964411B1 (ko) * 2002-01-18 2010-06-15 바이오겐 아이덱 엠에이 인코포레이티드 생물학적 활성 화합물과 컨쥬게이팅되는 잔기를 갖는 폴리알킬렌 글리콜
EP1591467A1 (en) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
US7157546B2 (en) 2002-09-09 2007-01-02 Nektar Therapeutics Al, Corporation Water-soluble polymer alkanals
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
ES2349743T3 (es) * 2003-10-10 2011-01-11 Novo Nordisk A/S Derivados de la il-21.
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
RU2385879C2 (ru) * 2004-01-21 2010-04-10 Ново Нордиск Хелс Кеа Аг Способ конъюгации пептидов, опосредованной трансглутаминазой
AP2007003919A0 (en) * 2004-08-31 2007-02-28 Pharmacia & Upjohn Co Llc Glycerol branched polyethylene glycol human growthhormone conjugates, process for their prepation a nd methods of use thereof
SG161210A1 (en) * 2004-12-22 2010-05-27 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
KR20070090023A (ko) * 2004-12-22 2007-09-04 암브룩스, 인코포레이티드 변형 인간 성장 호르몬
DK2399893T3 (en) * 2004-12-22 2018-10-08 Ambrx Inc COMPOSITIONS CONTAINING, INVOLVING PROCEDURES, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES
WO2006084888A2 (en) 2005-02-10 2006-08-17 Novo Nordisk A/S C-terminally pegylated growth hormones
EP1877439B1 (en) 2005-04-18 2011-02-09 Novo Nordisk A/S Il-21 variants
AU2006286486A1 (en) 2005-08-30 2007-03-08 Novo Nordisk Health Care Ag Liquid formulations of pegylated growth hormone
RS51998B (en) * 2005-11-08 2012-04-30 Ambrx Inc. ACCELERATORS FOR MODIFICATION OF NON-NATURAL AMINO ACIDS AND NON-NATURAL AMINO ACID POLYPEPTIDES
EP1968635B1 (en) 2005-12-14 2014-09-17 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
AU2007271150A1 (en) 2006-07-07 2008-01-10 Novo Nordisk Health Care Ag New protein conjugates and methods for their preparation
CN101108895B (zh) * 2006-07-19 2011-10-26 北京键凯科技有限公司 聚乙二醇乙醛衍生物及其与药物的结合物
AU2007310777A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S IL-21 variants
CL2008002399A1 (es) 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
ES2453946T3 (es) 2008-04-03 2014-04-09 Biosteed Gene Expression Tech. Co., Ltd. Hormona del crecimiento modificada con polietilenglicol bicatenario, método de preparación y aplicación de esta
KR101104574B1 (ko) * 2008-05-14 2012-01-11 성균관대학교산학협력단 폴리에틸렌글리콜로 화학적으로 수식된 인간 성장 호르몬, 이의 제조방법 및 용도
JP5639585B2 (ja) * 2008-07-31 2014-12-10 ファーマエッセンティア コーポレイション ペプチド−ポリマー共役体
MX2011000847A (es) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
RU2409669C9 (ru) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Способ иммобилизации биологически активного вещества (бав) на носитель (варианты) и конъюгат бав-носитель, полученный данными способами
JP5766118B2 (ja) * 2008-09-11 2015-08-19 ウェルズ ファーゴ バンク ナショナル アソシエイション ポリマー性アルファ−ヒドロキシアルデヒドおよびケトン反応剤ならびに抱合方法
US8513192B2 (en) 2009-01-22 2013-08-20 Novo Nordisk A/S Stable growth hormone compounds resistant to proteolytic degradation
JP6086528B2 (ja) 2009-08-06 2017-03-01 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 長期のインビボ有効性を有する成長ホルモン
SG181648A1 (en) 2009-12-15 2012-07-30 Ascendis Pharma As Dry growth hormone composition transiently linked to a polymer carrier
RU2012134974A (ru) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг Стабилизированное соединение гормона роста
TWI508737B (zh) 2010-01-22 2015-11-21 諾佛 儂迪克股份有限公司 具有延長的活體內功效的生長激素
NZ603399A (en) * 2010-05-17 2014-09-26 Cebix Inc Pegylated c-peptide
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
EA019967B1 (ru) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Ковалентный конъюгат полиэтиленгликоля с гормоном роста человека
ES2841123T3 (es) 2013-04-05 2021-07-07 Formulacion Del Compuesto De La Hormona De Crecimiento Formulación del compuesto de la hormona de crecimiento
EP4282485A3 (en) 2014-11-06 2024-01-17 PharmaEssentia Corporation Dosage regimen for pegylated interferon
IL254389B2 (en) * 2015-03-11 2023-03-01 Nektar Therapeutics Polymer conjugates and the il–7 group
SG11201802180TA (en) 2015-09-18 2018-04-27 Univ Miyazaki Long-acting adrenomedullin derivative
CN114539384A (zh) * 2020-11-19 2022-05-27 江苏众红生物工程创药研究院有限公司 聚乙二醇化长效生长激素及其制备方法和医药应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
DK0458064T3 (da) * 1990-05-04 1998-04-27 American Cyanamid Co Stabilisering af somatotropiner ved modificering af cysteinrester
CA2101918A1 (en) * 1991-03-18 1992-09-19 Samuel Zalipsky Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DE69635026T2 (de) * 1995-09-21 2006-05-24 Genentech Inc., San Francisco Varianten des menschlichen wachstumshormons
DE69838552T2 (de) * 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville Derivate des wachstumshormons und verwandte proteine
CA2359345A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
ES2204509T3 (es) * 1999-01-29 2004-05-01 F. Hoffmann-La Roche Ag Conjugados de gcsf.
WO2001076639A2 (en) * 2000-04-06 2001-10-18 Pharmacia Corporation Chemically-modified myelopoietin conjugates
WO2002055532A2 (en) * 2001-01-11 2002-07-18 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds

Also Published As

Publication number Publication date
EA200700431A1 (ru) 2008-02-28
OA13063A (en) 2006-11-10
KR20050044858A (ko) 2005-05-13
PL374354A1 (en) 2005-10-17
MXPA04004809A (es) 2004-08-11
EP1453859A2 (en) 2004-09-08
HUP0500997A2 (en) 2007-11-28
TNSN04090A1 (fr) 2006-06-01
JP2005525302A (ja) 2005-08-25
BR0214451A (pt) 2006-05-30
CN1608079A (zh) 2005-04-20
JP2006321808A (ja) 2006-11-30
HRP20040448A2 (en) 2006-02-28
CO5580794A2 (es) 2005-11-30
AU2002356990A1 (en) 2003-06-10
IL162031A0 (en) 2005-11-20
WO2003044056A2 (en) 2003-05-30
ECSP045114A (es) 2004-07-23
RS53104A (en) 2006-10-27
IS7268A (is) 2004-05-17
EA200400565A1 (ru) 2005-06-30
ZA200403907B (en) 2007-12-27
CA2467731A1 (en) 2003-05-30
AP2004003050A0 (en) 2004-06-30
MA27544A1 (fr) 2005-10-03
NO20042182L (no) 2004-08-11
KR20070072924A (ko) 2007-07-06
WO2003044056A3 (en) 2003-08-21
EA008505B1 (ru) 2007-06-29

Similar Documents

Publication Publication Date Title
GEP20063860B (en) Chemically-modified human growth hormone conjugates
JPH02504279A (ja) インスリン様成長因子１（ｉｇｆ‐１）または因子２（ｉｇｆ‐２）の類縁ペプチド
EA200000601A1 (ru) Сайт - специфичное получение конъюгатов grf с полиэтиленгликолем
HUT75533A (en) Improved interferon polymer conjugates
BG100236A (en) Sheared keratiocytic growth factor (kgf) of increased biological activity
MX172600B (es) , "procedimiento para la produccion de una proteina biologicamente activa
DE69531332D1 (de) Klonierung und Expression eines Gens, das Bryodin 1 aus Bryonia dioica kodiert
UA66857C2 (uk) КОН'ЮГАТ ПОЛІОЛ-<font face="Symbol">b</font>-ІНТЕРФЕРОН, СПОСІБ ОДЕРЖАННЯ КОН'ЮГАТУ ПОЛІОЛ-<font face="Symbol">b</font>-ІНТЕРФЕРОН ТА СПОСІБ ЛІКУВАННЯ ІНФЕКЦІЙНИХ ХВОРОБ, ПУХЛИН І АУТОІМУННИХ І ЗАПАЛЬНИХ ЗАХВОРЮВАНЬ
MXPA02006215A (es) Metodo para preparar esteres de 1-benzotriazolil carbonato de poli(etilenglicol).
AR044024A1 (es) Mutante de sustitucion de la il-18 humana, composicion biologicamente activa que la comprende, su uso para preparar dicha composicion, metodo para prepararla y metodo para mejorar la farmacocinetica y farmacodinamica de dicha il-18 humana
AU2005232475A1 (en) Novel g-csf conjugates
KR20070108535A (ko) 폴리펩티드와 5당류의 접합체
NZ517012A (en) Peptides that lower blood glucose levels
WO2003061577A8 (en) Polyalkylene glycol with moiety for conjugating biologically active compound
GB2355009A (en) Peptides conjugated to bile acids/salts
EP1763535B1 (de) Mit einem organischem rest verbundenes polypeptid
AU5956398A (en) Remedies for lymphocytic tumors
WO2002055532A3 (en) Variant growth hormone molecules conjugated with macromolecular compounds
CA2444266A1 (en) Use of bile acid or bile salt fatty acid conjugates
AR042103A1 (es) Conjugados de hormona de crecimiento humana pegilados n- terminales y proceso para su preparacion
EP1382352A1 (de) Bisacyloxypropylcystein-Konjugate und deren Verwendung
YU68702A (sh) Novi lhrh-antagonisti, njihova proizvodnja i upotreba kao leka
BR0213821A (pt) Conjugados de polìmero/peptìdeo timosina alfa 1
KR890700606A (ko) 생물학적 활성분자
KR960000921A (ko) 칼시토닌 유도체 및 그 용도